KEYNOTE-G05: Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Oct 3, 2026 - P1/2 | N=35 | Active, not recruiting | Sponsor: BioInvent International AB | Trial completion date: Dec 2025 ➔ Jul 2027 | Trial primary completion date: Dec 2025 ➔ Sep 2026
Trial completion date • Trial primary completion date • Eye Cancer • Melanoma • Oncology • Solid Tumor • Uveal Melanoma • BRAF
|